Differential Methylation in <i>APOE</i> (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects with Mild Cognitive Impairment
Background: Biomarkers are essential for identification of individuals at high risk of mild cognitive impairment (MCI) for potential prevention of dementia. We investigated DNA methylation in the <i>APOE</i> gene and apolipoprotein E (ApoE) plasma levels as MCI biomarkers in Colombian su...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/6/1394 |
id |
doaj-387084542dc448d4a388ec41197af588 |
---|---|
record_format |
Article |
spelling |
doaj-387084542dc448d4a388ec41197af5882020-11-24T20:54:36ZengMDPI AGInternational Journal of Molecular Sciences1422-00672019-03-01206139410.3390/ijms20061394ijms20061394Differential Methylation in <i>APOE</i> (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects with Mild Cognitive ImpairmentOscar Mancera-Páez0Kelly Estrada-Orozco1María Fernanda Mahecha2Francy Cruz3Kely Bonilla-Vargas4Nicolás Sandoval5Esneyder Guerrero6David Salcedo-Tacuma7Jesús D. Melgarejo8Edwin Vega9Jenny Ortega-Rojas10Gustavo C. Román11Rodrigo Pardo-Turriago12Humberto Arboleda13Department of Neurology, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaNeurosciences Research Group, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaGenetic Institute, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaNeurosciences Research Group, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaNeurosciences Research Group, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaGenetic Institute, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaGenetic Institute, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaGenetic Institute, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaGenetic Institute, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaNeurosciences Research Group, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaGenetic Institute, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaDepartment of Neurology, Methodist Neurological Institute and the Institute for Academic Medicine Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX 77030, USADepartment of Neurology, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaNeurosciences Research Group, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá ZC 57, ColombiaBackground: Biomarkers are essential for identification of individuals at high risk of mild cognitive impairment (MCI) for potential prevention of dementia. We investigated DNA methylation in the <i>APOE</i> gene and apolipoprotein E (ApoE) plasma levels as MCI biomarkers in Colombian subjects with MCI and controls. Methods: In total, 100 participants were included (71% women; average age, 70 years; range, 43–91 years). MCI was diagnosed by neuropsychological testing, medical and social history, activities of daily living, cognitive symptoms and neuroimaging. Using multivariate logistic regression models adjusted by age and gender, we examined the risk association of MCI with plasma ApoE and <i>APOE</i> methylation. Results: MCI was diagnosed in 41 subjects (average age, 66.5 ± 9.6 years) and compared with 59 controls. Elevated plasma ApoE and <i>APOE</i> methylation of CpGs 165, 190, and 198 were risk factors for MCI (<i>p</i> < 0.05). Higher CpG-227 methylation correlated with lower risk for MCI (<i>p</i> = 0.002). Only CpG-227 was significantly correlated with plasma ApoE levels (correlation coefficient = −0.665; <i>p</i> = 0.008). Conclusion: Differential <i>APOE</i> methylation and increased plasma ApoE levels were correlated with MCI. These epigenetic patterns require confirmation in larger samples but could potentially be used as biomarkers to identify early stages of MCI.https://www.mdpi.com/1422-0067/20/6/1394<i>APOE</i> geneapolipoprotein EDNA methylationmild cognitive impairmentHispanics |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Oscar Mancera-Páez Kelly Estrada-Orozco María Fernanda Mahecha Francy Cruz Kely Bonilla-Vargas Nicolás Sandoval Esneyder Guerrero David Salcedo-Tacuma Jesús D. Melgarejo Edwin Vega Jenny Ortega-Rojas Gustavo C. Román Rodrigo Pardo-Turriago Humberto Arboleda |
spellingShingle |
Oscar Mancera-Páez Kelly Estrada-Orozco María Fernanda Mahecha Francy Cruz Kely Bonilla-Vargas Nicolás Sandoval Esneyder Guerrero David Salcedo-Tacuma Jesús D. Melgarejo Edwin Vega Jenny Ortega-Rojas Gustavo C. Román Rodrigo Pardo-Turriago Humberto Arboleda Differential Methylation in <i>APOE</i> (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects with Mild Cognitive Impairment International Journal of Molecular Sciences <i>APOE</i> gene apolipoprotein E DNA methylation mild cognitive impairment Hispanics |
author_facet |
Oscar Mancera-Páez Kelly Estrada-Orozco María Fernanda Mahecha Francy Cruz Kely Bonilla-Vargas Nicolás Sandoval Esneyder Guerrero David Salcedo-Tacuma Jesús D. Melgarejo Edwin Vega Jenny Ortega-Rojas Gustavo C. Román Rodrigo Pardo-Turriago Humberto Arboleda |
author_sort |
Oscar Mancera-Páez |
title |
Differential Methylation in <i>APOE</i> (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects with Mild Cognitive Impairment |
title_short |
Differential Methylation in <i>APOE</i> (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects with Mild Cognitive Impairment |
title_full |
Differential Methylation in <i>APOE</i> (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects with Mild Cognitive Impairment |
title_fullStr |
Differential Methylation in <i>APOE</i> (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects with Mild Cognitive Impairment |
title_full_unstemmed |
Differential Methylation in <i>APOE</i> (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects with Mild Cognitive Impairment |
title_sort |
differential methylation in <i>apoe</i> (chr19; exon four; from 44,909,188 to 44,909,373/hg38) and increased apolipoprotein e plasma levels in subjects with mild cognitive impairment |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2019-03-01 |
description |
Background: Biomarkers are essential for identification of individuals at high risk of mild cognitive impairment (MCI) for potential prevention of dementia. We investigated DNA methylation in the <i>APOE</i> gene and apolipoprotein E (ApoE) plasma levels as MCI biomarkers in Colombian subjects with MCI and controls. Methods: In total, 100 participants were included (71% women; average age, 70 years; range, 43–91 years). MCI was diagnosed by neuropsychological testing, medical and social history, activities of daily living, cognitive symptoms and neuroimaging. Using multivariate logistic regression models adjusted by age and gender, we examined the risk association of MCI with plasma ApoE and <i>APOE</i> methylation. Results: MCI was diagnosed in 41 subjects (average age, 66.5 ± 9.6 years) and compared with 59 controls. Elevated plasma ApoE and <i>APOE</i> methylation of CpGs 165, 190, and 198 were risk factors for MCI (<i>p</i> < 0.05). Higher CpG-227 methylation correlated with lower risk for MCI (<i>p</i> = 0.002). Only CpG-227 was significantly correlated with plasma ApoE levels (correlation coefficient = −0.665; <i>p</i> = 0.008). Conclusion: Differential <i>APOE</i> methylation and increased plasma ApoE levels were correlated with MCI. These epigenetic patterns require confirmation in larger samples but could potentially be used as biomarkers to identify early stages of MCI. |
topic |
<i>APOE</i> gene apolipoprotein E DNA methylation mild cognitive impairment Hispanics |
url |
https://www.mdpi.com/1422-0067/20/6/1394 |
work_keys_str_mv |
AT oscarmancerapaez differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment AT kellyestradaorozco differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment AT mariafernandamahecha differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment AT francycruz differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment AT kelybonillavargas differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment AT nicolassandoval differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment AT esneyderguerrero differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment AT davidsalcedotacuma differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment AT jesusdmelgarejo differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment AT edwinvega differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment AT jennyortegarojas differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment AT gustavocroman differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment AT rodrigopardoturriago differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment AT humbertoarboleda differentialmethylationiniapoeichr19exonfourfrom44909188to44909373hg38andincreasedapolipoproteineplasmalevelsinsubjectswithmildcognitiveimpairment |
_version_ |
1716793928407056384 |